MedTech Valuations Hit Bottom; Recovery Inflection Point Expected in 2027

Overview

This report presents a 'down but not out' view on the recently underperforming MedTech sector. Despite lagging the S&P 500 for three consecutive years and facing capital outflows due to AI investment fervor, JPMorgan believes current valuations are highly attractive. Large-cap MedTech companies trade at 14–15x forward P/E, a 30% discount to the S&P 500—the widest in 30 years. The report forecasts that with a new innovation cycle launching in 2027–2028 and re-accelerating organic sales, the sector is poised for valuation recovery and share price rebound.

Core views

Valuation and Capital Flow Analysis: The primary pressure on MedTech stems from capital reallocation. Since ChatGPT’s launch, roughly 75–85% of S&P 500 index attribution and EPS growth has come from AI-related companies, forcing generalist fund managers to overweight AI to beat benchmarks—leading to divestment from healthcare. Additionally, GLP-1 weight-loss drug enthusiasm has further diverted capital. Currently, large-cap MedTech trades at just 14–15x earnings—not only below historical averages but exhibiting a rare 'inversion': low-growth companies now trade at higher multiples than high-growth peers. This extreme compression is seen as an attractive entry point. Historical Comparison and Growth Drivers: The report draws parallels to the 2010–2012 period post-Great Recession, when MedTech achieved re-accelerated organic sales growth—from +2.4% in 2012 to +5.4% in 2019—driven by innovations like continuous glucose monitoring (CGM) and structural heart interventions (TAVR/LAAC), which also expanded valuation premiums. While current macro headwinds (e.g., Medicare payment reforms, hospital consolidation) exist, they lack the secular, long-term drag seen during the Great Recession. The report contends that once organic growth re-accelerates, stock performance will follow. Future Catalysts and Innovation Cycle: 2026 is viewed as a catalyst-light year, but 2027–2028 will be highly eventful. Key innovation areas include: 1. Renal Denervation (RDN): A new hypertension treatment market. Boston Scientific’s TIVUS ultrasound system is expected to launch in 2028, while Medtronic’s Simplicity Spyral is advancing. 2. PFA for Type 2 Diabetes: Boston Scientific-backed Endogenex is developing a pulsed field ablation (PFA) device targeting duodenal dysfunction to control type 2 diabetes. Key data is expected in H1 2027. 3. Intravascular Lithotripsy (IVL): Both Boston Scientific and Abbott plan coronary IVL device launches in 2027 to challenge Shockwave’s dominance. 4. Structural Heart: Edwards has multiple product lines in mitral and tricuspid valve replacement/repair, expected to drive growth over the coming years. Interest Rate Environment Impact: Over the past 30 years, MedTech stocks have significantly outperformed in falling-rate environments (~15.5% annualized relative return vs. 4.7% in rising-rate regimes). With the Fed signaling a patient, data-dependent policy path, a stable or declining rate environment would provide favorable macro tailwinds for the sector.

Analysis framework

The report employs a framework combining 'historical analogy + valuation percentile analysis + pipeline mapping.' First, by comparing the post-Great Recession recovery path (2010–2012), it argues the current sector weakness reflects a cyclical trough—not secular decline—and that innovation-driven rebounds have historical precedent. Second, using relative valuation, it calculates the MedTech sector’s premium/discount versus the S&P 500, highlighting the current 30% discount as a 30-year extreme, suggesting mean reversion potential. Finally, by detailing specific 2026–2028 product pipelines (catalysts), it translates abstract 'innovation' into concrete revenue drivers, providing micro-level support for the 2027 recovery thesis.

Methodology notes

• Valuation MethodPE/PEG valuation

  Relative Valuation Premium/Discount Analysis

  The report compares the MedTech sector’s NTM PE (next-twelve-months price-to-earnings) to the S&P 500’s PE to calculate relative premium or discount percentages. A historically extreme discount (e.g., 30% in this report) is typically interpreted as a valuation floor signal.

• Industry/Sector Analysis FrameworkPenetration S-curve

  New Product Adoption Cycle

  The report analyzes the market introduction of new technologies like renal denervation (RDN), noting stages such as physician education, overcoming clinical stigma, and identifying optimal patient populations—consistent with early-phase S-curve adoption dynamics.

• Macroeconomic frameworkInterest rate parity

  Interest Rate Sensitivity Analysis

  The report examines MedTech stock relative performance across different interest rate regimes (rising, falling, stable) over the past 30 years, finding stronger outperformance in declining-rate environments. This constitutes a historical-data-driven macro factor sensitivity analysis.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Intuitive Surgical (ISRG)

  Top large-cap pick; fundamentals strong, AI concerns overblown

  Strengths

  Large installed base and procedure volume provide advantages in building proprietary AI capabilities; Q1 2026 results beat expectations

  Weaknesses

  Absolute valuation relatively high (~40x NTM PE), though below historical levels

  Comparison

  Offers greater growth certainty and wider moat compared to other large caps

  Risks

  Excessive market fear of AI disruption

• Edwards Lifesciences (EW)

  Consensus long idea; leader in structural heart

  Strengths

  Positive Partner 3 low-risk data; strong momentum in TMTT with Pascal and Evoque; double-digit growth

  Comparison

  Has the most 'shots on goal' (pipeline depth) in structural heart

  Risks

  Uncertainty whether TAVR label expansion drives pull-forward rather than sustained growth

• Stryker (SYK)

  Strong execution; consistent high growth

  Strengths

  CEO leadership widely respected; maintains high-single-digit growth via internal innovation and M&A; specialized sales network

  Comparison

  One of the most consistently executed high-quality growth MedTech companies in recent years

  Risks

  One-off disruptions like cybersecurity challenges

• Boston Scientific (BSX)

  Most controversial yet most undervalued; high upside potential

  Strengths

  Strong WATCHMAN growth driver; portfolio includes high-potential assets like Endogenex (PFA for diabetes)

  Weaknesses

  Conservative guidance; requires several quarters to rebuild bull confidence

  Comparison

  Bears see it as 'dead money' through end-2026, but bulls believe its strategic positioning is deep and forward-looking

  Risks

  Guidance misses; insufficient share buyback力度

• Glaukos (GKOS)

  Top small/mid-cap pick; profitability inflection near

  Strengths

  iDose and EpiOXA guidance conservative; clear beat-and-raise potential; profitability is a matter of time

  Comparison

  Offers the clearest upside path among small/mid-caps

  Risks

  Commercialization delays

• Insulet (PODD)

  Best positioned in insulin pump market; extremely cheap valuation

  Strengths

  Trading at 3.0x NTM Sales and 22x Earnings—too cheap given its market position

  Weaknesses

  Poor sentiment; bear thesis hard to disprove

  Comparison

  More fundamentally sound than peers but more pessimistically priced

  Risks

  Intensifying competition; slowing insulin pump market growth

Key data

• Large-Cap MedTech NTM PE14–15x~30% discount to S&P 500; widest in 30 years
• Small/Mid-Cap MedTech EV/Sales2.2xFar below Russell 2000’s ~2.0x (Note: Historically, MedTech traded at higher multiples; this highlights extreme compression)
• AI-Related Capital Investment Share~90%Since ChatGPT’s launch, ~90% of S&P 500 capital investment has flowed to AI-related companies
• Relative Return in Falling-Rate Environments~15.5%Annualized relative return for MedTech over past 30 years in declining-rate periods, significantly higher than 4.7% in rising-rate periods

Impact & implications

For investors, the current MedTech sector offers exceptional margin of safety and potential for reversal gains. While near-term catalysts are limited, the robust 2027 product pipeline—especially in structural heart, renal denervation, and diabetes therapeutics—could reignite long-term investor interest. A stable or accommodative rate environment would further amplify this tailwind. Investors should focus on high-quality leaders with strong execution capabilities, clear innovation roadmaps, and unjustifiably compressed valuations.

Risks

• Prolonged capital outflows from MedTech due to sustained AI investment frenzy
• Macroeconomic recession reducing elective procedure volumes
• Tighter Medicare reimbursement policies or pricing transparency pressures
• Clinical trial failures or regulatory delays for new products
• Geopolitical risks disrupting supply chains or global demand

What to watch

• 2027 launch and physician adoption of renal denervation (RDN) products
• Key data from Endogenex’s ReCET system for PFA treatment of type 2 diabetes (expected H1 2027)
• FDA approval and commercial launch of Boston Scientific and Abbott’s coronary IVL devices (expected 2027)
• Next-generation mitral/tricuspid product progress from Edwards Lifesciences
• Marginal impact of Fed rate trajectory on sector valuations